Isolation and characterization of two novel bacteriophages against carbapenem-resistant Klebsiella pneumoniae

IF 4.6 2区医学 Q2 IMMUNOLOGY

Frontiers in Cellular and Infection Microbiology Pub Date : 2024-08-29 DOI:10.3389/fcimb.2024.1421724

Abrar Senhaji-Kacha, Mireia Bernabéu-Gimeno, Pilar Domingo-Calap, John Jairo Aguilera-Correa, Mateo Seoane-Blanco, Sara Otaegi-Ugartemendia, Mark J. van Raaij, Jaime Esteban, Meritxell García-Quintanilla

{"title":"Isolation and characterization of two novel bacteriophages against carbapenem-resistant Klebsiella pneumoniae","authors":"Abrar Senhaji-Kacha, Mireia Bernabéu-Gimeno, Pilar Domingo-Calap, John Jairo Aguilera-Correa, Mateo Seoane-Blanco, Sara Otaegi-Ugartemendia, Mark J. van Raaij, Jaime Esteban, Meritxell García-Quintanilla","doi":"10.3389/fcimb.2024.1421724","DOIUrl":null,"url":null,"abstract":"The increase of antibiotic-resistant bacteria has become a global health emergency and the need to explore alternative therapeutic options arises. Phage therapy uses bacteriophages to target specific bacterial strains. Phages are highly specific and can target resistant bacteria. Currently, research in this regard is focused on ensuring reliability and safety to bring this tool into clinical practice. The first step is to conduct comprehensive preclinical research. In this work, we present two novel bacteriophages vB_Kpn_F13 and vB_Kpn_F14 isolated against clinical carbapenem-resistant Klebsiella pneumoniae strains obtained from hospital sewage. Multiple studies in vitro were conducted, such as sequencing, electron microscopy, stability, host range infectivity, planktonic effect and biofilm inhibition in order to discover their ability to be used against carbapenem-resistant K. pneumoniae pathogens causing difficult-to-treat infections.","PeriodicalId":12458,"journal":{"name":"Frontiers in Cellular and Infection Microbiology","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cellular and Infection Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcimb.2024.1421724","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The increase of antibiotic-resistant bacteria has become a global health emergency and the need to explore alternative therapeutic options arises. Phage therapy uses bacteriophages to target specific bacterial strains. Phages are highly specific and can target resistant bacteria. Currently, research in this regard is focused on ensuring reliability and safety to bring this tool into clinical practice. The first step is to conduct comprehensive preclinical research. In this work, we present two novel bacteriophages vB_Kpn_F13 and vB_Kpn_F14 isolated against clinical carbapenem-resistant Klebsiella pneumoniae strains obtained from hospital sewage. Multiple studies in vitro were conducted, such as sequencing, electron microscopy, stability, host range infectivity, planktonic effect and biofilm inhibition in order to discover their ability to be used against carbapenem-resistant K. pneumoniae pathogens causing difficult-to-treat infections.

查看原文本刊更多论文

针对耐碳青霉烯类肺炎克雷伯氏菌的两种新型噬菌体的分离与鉴定

抗生素耐药细菌的增加已成为全球健康的一个紧急问题，因此需要探索替代疗法。噬菌体疗法利用噬菌体来针对特定的细菌菌株。噬菌体具有高度特异性，可针对抗药性细菌。目前，这方面的研究重点是确保可靠性和安全性，以便将这一工具应用于临床实践。第一步是开展全面的临床前研究。在这项工作中，我们介绍了从医院污水中分离出的两种新型噬菌体 vB_Kpn_F13 和 vB_Kpn_F14，这两种噬菌体针对的是临床上耐碳青霉烯类药物的肺炎克雷伯菌株。研究人员对这两种噬菌体进行了多种体外研究，如测序、电子显微镜、稳定性、宿主范围感染性、浮游生物效应和生物膜抑制等，以发现这两种噬菌体可用于抗耐碳青霉烯类肺炎克雷伯氏菌病原体引起的难治性感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Cellular and Infection Microbiology IMMUNOLOGY-MICROBIOLOGY

CiteScore

7.90

自引率

7.00%

发文量

1817

审稿时长

14 weeks

期刊介绍： Frontiers in Cellular and Infection Microbiology is a leading specialty journal, publishing rigorously peer-reviewed research across all pathogenic microorganisms and their interaction with their hosts. Chief Editor Yousef Abu Kwaik, University of Louisville is supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Cellular and Infection Microbiology includes research on bacteria, fungi, parasites, viruses, endosymbionts, prions and all microbial pathogens as well as the microbiota and its effect on health and disease in various hosts. The research approaches include molecular microbiology, cellular microbiology, gene regulation, proteomics, signal transduction, pathogenic evolution, genomics, structural biology, and virulence factors as well as model hosts. Areas of research to counteract infectious agents by the host include the host innate and adaptive immune responses as well as metabolic restrictions to various pathogenic microorganisms, vaccine design and development against various pathogenic microorganisms, and the mechanisms of antibiotic resistance and its countermeasures.